Myfanwy Graham

发表

Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies

B. Betz-Stablein, S. Nielsen, B. Le Foll, 2022, Neuropsychopharmacology.

Translational hurdles with cannabis medicines

W. Hall, Jennifer H. Martin, C. Lucas, 2020, Pharmacoepidemiology and drug safety.

Over the counter low-dose cannabidiol: A viewpoint from the ACRE Capacity Building Group

L. Greenwood, Y. Bonomo, E. Eden, 2021, Journal of psychopharmacology.

Cannabidiol drug interaction considerations for prescribers and pharmacists

B. Murnion, C. Lucas, Jennifer H Martin, 2022, Expert review of clinical pharmacology.

Expert advice for prescribing cannabis medicines for patients with epilepsy—drawn from the Australian clinical experience

J. Lawson, N. Lawn, Jennifer H Martin, 2022, British journal of clinical pharmacology.

From growers to patients: Multi-stakeholder views on the use of, and access to medicinal cannabis in Australia

P. Scuffham, L. Greenwood, D. Erku, 2022, PloS one.

Medicinal Cannabis Guidance and Resources for Health Professionals to Inform Clinical Decision Making.

C. Lucas, J. Schneider, Myfanwy Graham, 2023, Clinical therapeutics.

Avoiding the Premature Introduction of Psychedelic Medicines in Alzheimer’s Disease and Related Disorders

A. Carter, J. Gardner, W. Hall, 2023, AJOB neuroscience.

A provisional evaluation of Australia's medical cannabis program.

D. Stjepanović, Vivian Chiu, Myfanwy Graham, 2023, The International journal on drug policy.

'The wild west of medicine': A qualitative investigation of the factors influencing Australian health-care practitioners' delivery of medicinal cannabis.

Myfanwy Graham, Adrian Carter, Olivia Dobson, 2024, Drug and Alcohol Review.